PRGO Perrigo Company plc
Legal ·
The 10-Q names Perrigo, CFO Eduardo Bezerra and former CEOs Patrick Lockwood-Taylor and Murray Kessler in French v. Perrigo. A Teamsters pension fund is lead plaintiff and filed an amended complaint on May 1, 2026.
Perrigo (NYSE: PRGO) received €305.6 million at closing and may get up to €27.0 million more over three years. The company says net proceeds will be used primarily to reduce debt.
Perrigo Company plc describes itself as a pure-play self-care company, with more than a century of providing health and wellness solutions and no single product representing more than 5% of total revenue. In North America, Perrigo is a store brand private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. In Europe its portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula and ACO. Its Consumer Self-Care Americas segment covers the U.S. and Canada, and its Consumer Self-Care International segment covers markets outside the U.S. and Canada, primarily Europe and Australia. Beginning in the first quarter of 2026, the company began transitioning to a category-based segment view. Its prescription business, including generic prescription pharmaceuticals in the U.S. and other pharmaceuticals and diagnostics in Israel, has been divested and is reported as discontinued operations. The company's plan to drive cash flow is built on a Three-S approach of stabilizing, streamlining and strengthening its businesses.
| Product or program | What it is | Stage |
|---|---|---|
| Opill | Brand in the North American self-care portfolio | |
| Mederma | Brand in the North American self-care portfolio | |
| Compeed | Brand in the European portfolio | |
| Store brand self-care products | Private label self-care products for North American retailers |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $95.4 million | $112.2 million |
| Net income (loss) | -$1.43 billion | -$171.8 million |
| Cash from operations | $238.5 million | $362.9 million |
| Cash and equivalents | $531.6 million | $558.8 million |
Our latest story on this, dated Aug 5, 2026: "Perrigo faces New York securities class action over infant formula statements". The story links the filing or release it is based on. Read the story.
Perrigo Company plc trades under the ticker PRGO on NYSE.
Perrigo Company plc is listed on NYSE. Our directory also records these other listings: BMFBOVESPA:P1RG34; GETTEX:PIG; LS:A1XAEY; LSE:0Y5E; LSX:A1XAEY.
The SEC Central Index Key (CIK) for Perrigo Company plc is 1585364. Its filings are on SEC EDGAR.
138,769,245 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Our directory records Perrigo Company plc under United States.
Our directory classifies Perrigo Company plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Perrigo Company plc is IE00BGH1M568.
aibio.space lists Perrigo Company plc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as L2.
Perrigo Company plc describes itself as a pure-play self-care company, with more than a century of providing health and wellness solutions and no single product representing more than 5% of total revenue. In North America, Perrigo is a store brand private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma.
Opill: Brand in the North American self-care portfolio
Mederma: Brand in the North American self-care portfolio
Perrigo Company plc reported a net loss of $1.43 billion for the fiscal year ended Dec 31, 2025, and generated $238.5 million of cash from operations, per its annual report to the SEC.
$95.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio